Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. SMCI
6. GOOGL
7. RTX
8. COF
9. TSLA
10. META

Go back to Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021

Bristol-Myers Squibb Co. (BMY) PT Raised to $74 at BMO Capital

February 7, 2022 7:21 AM EST

BMO Capital analyst Evan David Seigerman raised the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $74.00 (from $72.00) while maintaining an Outperform rating.

The analyst commented, "Concerns around Revlimids erosion still overshadow the growth from the new product portfolio, but the... More

Bristol-Myers Squibb (BMY) Tops Q4 EPS by 1c

February 4, 2022 6:59 AM EST

Bristol-Myers Squibb (NYSE: BMY) reported Q4 EPS of $1.83, $0.01 better than the analyst estimate of $1.82. Revenue for the quarter came in at $12 billion versus the consensus estimate of $12.12 billion.

GUIDANCE:

Bristol-Myers Squibb sees FY2022 EPS of $7.65-$7.95.

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.

... More